Early trajectory of inflammatory cytokines following tarlatamab administration in three advanced SCLC patients

Abstract Tarlatamab, a bispecific T-cell engager (BiTE), effectively activates the immune system but often causes cytokine release syndrome (CRS). To understand the early in vivo cytokine dynamics of post-BiTE therapy, we analyzed serum from three SCLC patients before and after tarlatamab administra...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Takuma Imakita, Kohei Fujita, Yuki Yamamoto, Osamu Kanai, Yuta Okada, Shogo Toyama, Takanori Ito, Issei Oi, Kiminobu Tanizawa
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Springer 2025-11-01
coleção:	Cancer Immunology, Immunotherapy
Assuntos:	Small-cell lung cancer (SCLC) Tarlatamab Cytokine release syndrome (CRS) Inflammatory cytokines Bispecific T-cell engager (BiTE)
Acesso em linha:	https://doi.org/10.1007/s00262-025-04243-5
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!